Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Employees: 500
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
11% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 63
0% less funds holding
Funds holding: 415 [Q1] → 413 (-2) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 154
3.62% less ownership
Funds ownership: 77.98% [Q1] → 74.35% (-3.62%) [Q2]
36% less capital invested
Capital invested by funds: $9.14B [Q1] → $5.86B (-$3.28B) [Q2]
45% less call options, than puts
Call options by funds: $38.2M | Put options by funds: $69.1M
63% less funds holding in top 10
Funds holding in top 10: 16 [Q1] → 6 (-10) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$121
76%
upside
Avg. target
$129
87%
upside
High target
$137
99%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Edward Nash | 99%upside $137 | Buy Maintained | 1 Aug 2025 |
Piper Sandler David Amsellem | 76%upside $121 | Overweight Maintained | 1 Aug 2025 |
Financial journalist opinion
Based on 6 articles about CORT published over the past 30 days
Positive
Zacks Investment Research
17 hours ago
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Positive
Seeking Alpha
2 weeks ago
Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment issues, but true demand and revenue growth may be accelerating as a large new market is penetrated, pharmacy capacity expands, and new products launch. Physician adoption of Corcept's therapies is ramping earlier than we expected, supporting a long-term outlook for 30-50% annual revenue growth and significant market expansion.
Neutral
Seeking Alpha
3 weeks ago
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secretary Joseph K. Belanoff - Co-Founder, President, CEO & Director Roberto W.
Neutral
Zacks Investment Research
3 weeks ago
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Positive
Zacks Investment Research
3 weeks ago
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.32 per share a year ago.
Neutral
Business Wire
3 weeks ago
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results “The second quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a re.
Neutral
Business Wire
1 month ago
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access.
Positive
Zacks Investment Research
1 month ago
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Neutral
Business Wire
1 month ago
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant o.
Positive
Seeking Alpha
1 month ago
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modulators for rare diseases. Korlym's steady revenue growth can support Corcept's increased R&D for the foreseeable future.
Charts implemented using Lightweight Charts™